Neurotrophins in bladder function: What do we know and where do we go from here?

Neurourology and Urodynamics

Volumn 33, Issue 1, 2014, Pages 39-45

  Cruz, Célia Duarte ^a,b  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

bladderp pain syndrome interstitial cystitis; nerve growth factor; neurotrophins; overactive bladder

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLOPHOSPHAMIDE; LIPOPOLYSACCHARIDE; NERVE GROWTH FACTOR; NEUROTROPHIN; TURPENTINE;

ARTICLE; BLADDER DYSFUNCTION; BLADDER FUNCTION; CHRONIC PROSTATITIS; CYSTALGIA; DETRUSOR DYSSYNERGIA; HUMAN; NERVE FIBER GROWTH; NONHUMAN; OVERACTIVE BLADDER; PELVIS PAIN SYNDROME; PROSTATE HYPERTROPHY; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; URETHRA OBSTRUCTION;

BLADDERP PAIN SYNDROME/INTERSTITIAL CYSTITIS; NERVE GROWTH FACTOR; NEUROTROPHINS; OVERACTIVE BLADDER;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; NERVE GROWTH FACTORS; PROGNOSIS; SENSORY RECEPTOR CELLS; URINARY BLADDER; URINARY BLADDER DISEASES; UROTHELIUM;

EID: 84890312731     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22438     Document Type: Article

References (128)

1. Pezet S, McMahon SB,. Neurotrophins: Mediators and modulators of pain. Annu Rev Neurosci 2006; 29: 507-38.
2. Althaus HH, Kloppner S, Klopfleisch S, et al. Oligodendroglial cells and neurotrophins: A polyphonic cantata in major and minor. J Mol Neurosci 2008; 35: 65-79.
3. Teng KK, Felice S, Kim T, et al. Understanding proneurotrophin actions: Recent advances and challenges. Dev Neurobiol 2010; 70: 350-9.
4. Allen SJ, Dawbarn D,. Clinical relevance of the neurotrophins and their receptors. Clin Sci (Lond) 2006; 110: 175-91.
5. Steers WD, Kolbeck S, Creedon D, et al. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest 1991; 88: 1709-15.
6. Tuttle JB, Mackey T, Steers WD,. NGF, bFGF, and CNTF increase survival of major pelvic ganglion neurons cultured from the adult rat. Neurosci Lett 1994; 173: 94-8.
7. Tuttle JB, Steers WD,. Nerve growth factor responsiveness of cultured major pelvic ganglion neurons from the adult rat. Brain Res 1992; 588: 29-40.
8. Tuttle JB, Steers WD, Albo M, et al. Neural input regulates tissue NGF and growth of the adult rat urinary bladder. J Auton Nerv Syst 1994; 49: 147-58.
9. Steers WD, Meythaler JM, Haworth C, et al. Effects of acute bolus and chronic continuous intrathecal baclofen on genitourinary dysfunction due to spinal cord pathology. J Urol 1992; 148: 1849-55.
10. Persson K, Sando JJ, Tuttle JB, et al. Protein kinase C in cyclic stretch-induced nerve growth factor production by urinary tract smooth muscle cells. Am J Physiol 1995; 269: C1018-24.
11. Tanner R, Chambers P, Khadra MH, et al. The production of nerve growth factor by human bladder smooth muscle cells in vivo and in vitro. BJU Int 2000; 85: 1115-9.
12. Persson K, Steers WD, Tuttle JB,. Regulation of nerve growth factor secretion in smooth muscle cells cultured from rat bladder body, base, and urethra. J Urol 1997; 157: 2000-6.
13. Clemow DB, Steers WD, Tuttle JB,. Stretch-activated signaling of nerve growth factor secretion in bladder and vascular smooth muscle cells from hypertensive and hyperactive rats. J Cell Physiol 2000; 183: 289-300.
14. Lowe EM, Anand P, Terenghi G, et al. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol 1997; 79: 572-7.
15. Guerios SD, Wang ZY, Boldon K, et al. Blockade of NGF and Trk receptors inhibits increased peripheral mechanical sensitivity accompanying cystitis in rats. Am J Physiol Regul Integr Comp Physiol 2008; 295: R111-22.
16. Teng J, Wang ZY, Bjorling DE,. Estrogen-induced proliferation of urothelial cells is modulated by nerve growth factor. Am J Physiol Renal Physiol 2002; 282: F1075-83.
17. Murray E, Malley SE, Qiao LY, et al. Cyclophosphamide induced cystitis alters neurotrophin and receptor tyrosine kinase expression in pelvic ganglia and bladder. J Urol 2004; 172: 2434-9.
18. Klinger MB, Girard B, Vizzard MA,. p75NTR expression in rat urinary bladder sensory neurons and spinal cord with cyclophosphamide-induced cystitis. J Comp Neurol 2008; 507: 1379-92.
19. Klinger MB, Vizzard MA,. Role of p75NTR in female rat urinary bladder with cyclophosphamide-induced cystitis. Am J Physiol Renal Physiol 2008; 295: F1778-89.
20. Gazzano-Santoro H, Chen A, Casto B, et al. Validation of a rat pheochromocytoma (PC12)-based cell survival assay for determining biological potency of recombinant human nerve growth factor. J Pharm Biomed Anal 1999; 21: 945-59.
21. Chiarenza A, Lazarovici P, Lempereur L, et al. Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7. Cancer Res 2001; 61: 3002-8.
22. Nakagawara A, Brodeur GM,. Role of neurotrophins and their receptors in human neuroblastomas: A primary culture study. Eur J Cancer 1997; 33: 2050-3.
23. Sasaki K, Chancellor MB, Phelan MW, et al. Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root ganglia. J Urol 2002; 168: 1259-64.
24. Dmitrieva N, McMahon SB,. Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain 1996; 66: 87-97.
25. Dmitrieva N, Shelton D, Rice AS, et al. The role of nerve growth factor in a model of visceral inflammation. Neuroscience 1997; 78: 449-59.
26. Zvara P, Vizzard MA,. Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord. BMC Physiol 2007; 7: 9.
27. Lamb K, Gebhart GF, Bielefeldt K,. Increased nerve growth factor expression triggers bladder overactivity. J Pain 2004; 5: 150-6.
28. Schnegelsberg B, Sun TT, Cain G, et al. Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity, and changes in urinary bladder function. Am J Physiol Regul Integr Comp Physiol 2010; 298: R534-47.
29. Girard BM, Tompkins JD, Parsons RL, et al. Effects of CYP-induced cystitis on PACAP/VIP and receptor expression in micturition pathways and bladder function in mice with overexpression of NGF in urothelium. J Mol Neurosci 2012; 48: 730-43.
30. Yoshimura N, Bennett NE, Hayashi Y, et al. Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci 2006; 26: 10847-55.
31. Ochodnický P, Cruz CD, Yoshimura N, et al. Nerve growth factor in bladder dysfunction: Contributing factor, biomarker, and therapeutic target. Neurourol Urodyn 2011; 30: 1227-41.
32. Ochodnický P, Cruz CD, Yoshimura N, et al. Neurotrophins as regulators of urinary bladder function. Nat Rev Urol 2012; 9: 628-37.
33. Cruz CD, Avelino A, McMahon SB, et al. Increased spinal cord phosphorylation of extracellular signal-regulated kinases mediates micturition overactivity in rats with chronic bladder inflammation. Eur J Neurosci 2005; 21: 773-81.
34. Bjorling DE, Jacobsen HE, Blum JR, et al. Intravesical Escherichia coli lipopolysaccharide stimulates an increase in bladder nerve growth factor. BJU Int 2001; 87: 697-702.
35. Seki S, Sasaki K, Fraser MO, et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol 2002; 168: 2269-74.
36. Seki S, Sasaki K, Igawa Y, et al. Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J Urol 2004; 171: 478-82.
37. Kim JC, Kim DB, Seo SI, et al. Nerve growth factor and vanilloid receptor expression, and detrusor instability, after relieving bladder outlet obstruction in rats. BJU Int 2004; 94: 915-8.
38. Vizzard MA,. Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol 2000; 161: 273-84.
39. Liu HT, Kuo HC,. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007; 70: 463-8.
40. Liu B, Zheng BZ, Zhou ZL, et al. Change of nerve growth factor mRNA in human detrusor in bladder outlet obstruction with benign prostatic hyperplasia and their implication. Zhonghua Wai Ke Za Zhi 2004; 42: 874-6.
41. Birder LA, Wolf-Johnston A, Griffiths D, et al. Role of urothelial nerve growth factor in human bladder function. Neurourol Urodyn 2007; 26: 405-9.
42. Kaplan SA, Te AE, Blaivas JG,. Urodynamic findings in patients with diabetic cystopathy. J Urol 1995; 153: 342-4.
43. Kebapci N, Yenilmez A, Efe B, et al. Bladder dysfunction in type 2 diabetic patients. Neurourol Urodyn 2007; 26: 814-9.
44. Daneshgari F, Liu G, Birder L, et al. Diabetic bladder dysfunction: Current translational knowledge. J Urol 2009; 182: S18-26.
45. Steers WD, Creedon DJ, Tuttle JB,. Immunity to nerve growth factor prevents afferent plasticity following urinary bladder hypertrophy. J Urol 1996; 155: 379-85.
46. Hu VY, Zvara P, Dattilio A, et al. Decrease in bladder overactivity with REN1820 in rats with cyclophosphamide induced cystitis. J Urol 2005; 173: 1016-21.
47. Tyagi P, Banerjee R, Basu S, et al. Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates. Mol Pharm 2006; 3: 398-406.
48. Frias B, Charrua A, Pinto R, et al. Intrathecal blockade of Trk receptors and neurotrophin sequestration reduces pain and urinary frequency in an animal model of chronic bladder inflammation. Neurourol Urodyn 2009; 28: 708.
49. Lommatzsch M, Quarcoo D, Schulte-Herbruggen O, et al. Neurotrophins in murine viscera: A dynamic pattern from birth to adulthood. Int J Dev Neurosci 2005; 23: 495-500.
50. Lommatzsch M, Braun A, Mannsfeldt A, et al. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived neurotrophic functions. Am J Pathol 1999; 155: 1183-93.
51. Michael GJ, Averill S, Nitkunan A, et al. Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J Neurosci 1997; 17: 8476-90.
52. Stanzel RD, Lourenssen S, Blennerhassett MG,. Inflammation causes expression of NGF in epithelial cells of the rat colon. Exp Neurol 2008; 211: 203-13.
53. Pinto R, Frias B, Allen S, et al. Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience 2010; 166: 907-16.
54. Oddiah D, Anand P, McMahon SB, et al. Rapid increase of NGF, BDNF, and NT-3 mRNAs in inflamed bladder. Neuroreport 1998; 9: 1455-8.
55. Zvara P, Kliment J, Jr., DeRoss AL, et al. Differential expression of bladder neurotrophic factor mRNA in male and female rats after bladder outflow obstruction. J Urol 2002; 168: 2682-8.
56. Qiao LY, Vizzard MA,. Cystitis-induced upregulation of tyrosine kinase (TrkA, TrkB) receptor expression and phosphorylation in rat micturition pathways. J Comp Neurol 2002; 454: 200-11.
57. Qiao LY, Grider JR,. Up-regulation of calcitonin gene-related peptide and receptor tyrosine kinase TrkB in rat bladder afferent neurons following TNBS colitis. Exp Neurol 2007; 204: 667-79.
58. Zvarova K, Murray E, Vizzard MA,. Changes in galanin immunoreactivity in rat lumbosacral spinal cord and dorsal root ganglia after spinal cord injury. J Comp Neurol 2004; 475: 590-603.
59. Frias B, Charrua A, Santos J, et al. BDNF sequestration improves bladder function in spinal cord injured animals. Eur Urol Suppl 2012; 11: E368.
60. Kawakami T, Wakabayashi Y, Isono T, et al. Expression of neurotrophin messenger RNAs during rat urinary bladder development. Neurosci Lett 2002; 329: 77-80.
61. Vizzard MA, Wu KH, Jewett IT,. Developmental expression of urinary bladder neurotrophic factor mRNA and protein in the neonatal rat. Brain Res Dev Brain Res 2000; 119: 217-24.
62. Chao MV, Rajagopal R, Lee FS,. Neurotrophin signalling in health and disease. Clin Sci (Lond) 2006; 110: 167-73.
63. Reichardt LF,. Neurotrophin-regulated signalling pathways. Phil Trans R Soc B 2006; 361: 1545-64.
64. Galan A, Cervero F, Laird JM,. Extracellular signaling-regulated kinase-1 and -2 (ERK 1/2) mediate referred hyperalgesia in a murine model of visceral pain. Brain Res Mol Brain Res 2003; 116: 126-34.
65. Corrow KA, Vizzard MA,. Phosphorylation of extracellular signal-regulated kinases in urinary bladder in rats with cyclophosphamide-induced cystitis. Am J Physiol Regul Integr Comp Physiol 2007; 293: R125-34.
66. Corrow KA, Vizzard MA,. Phosphorylation of extracellular signal-regulated kinases in bladder afferent pathways with cyclophosphamide-induced cystitis. Neuroscience 2009; 163: 1353-62.
67. Chung CW, Zhang QL, Qiao LY,. Endogenous nerve growth factor regulates collagen expression and bladder hypertrophy through Akt and MAPK pathways during cystitis. J Biol Chem 2010; 285: 4206-12.
68. Malley SE, Vizzard MA,. Changes in urinary bladder cytokine mRNA and protein after cyclophosphamide-induced cystitis. Physiol Genom 2002; 9: 5-13.
69. Yu SJ, Xia CM, Kay JC, et al. Activation of extracellular signal-regulated protein kinase 5 is essential for cystitis- and nerve growth factor-induced calcitonin gene-related peptide expression in sensory neurons. Mol Pain 2012; 8: 48.
70. de Groat WC, Yoshimura N,. Afferent nerve regulation of bladder function in health and disease. Handb Exp Pharmacol 2009; 194: 91-138.
71. Lai HH, Qiu CS, Crock LW, et al. Activation of spinal extracellular signal-regulated kinases (ERK) 1/2 is associated with the development of visceral hyperalgesia of the bladder. Pain 2011; 152: 2117-24.
72. Qiao LY, Gulick MA,. Region-specific changes in the phosphorylation of ERK1/2 and ERK5 in rat micturition pathways following cyclophosphamide-induced cystitis. Am J Physiol Regul Integr Comp Physiol 2007; 292: R1368-75.
73. Cruz CD, Charrua A, Vieira E, et al. Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals. Exp Neurol 2008; 214: 301-8.
74. Cruz CD, McMahon SB, Cruz F,. Spinal ERK activation contributes to the regulation of bladder function in spinal cord injured rats. Exp Neurol 2006; 200: 66-73.
75. Frias B, Allen S, Dawbarn D, et al. Brain-derived neurotrophic factor, acting at the spinal cord level, participates in bladder hyperactivity and referred pain during chronic bladder inflammation. Neuroscience 2013; 234: 88-102.
76. Ji RR, Befort K, Brenner GJ, et al. ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. J Neurosci 2002; 22: 478-85.
77. Slack SE, Grist J, Mac Q, et al. TrkB expression and phospho-ERK activation by brain-derived neurotrophic factor in rat spinothalamic tract neurons. J Comp Neurol 2005; 489: 59-68.
78. Slack SE, Pezet S, McMahon SB, et al. Brain-derived neurotrophic factor induces NMDA receptor subunit one phosphorylation via ERK and PKC in the rat spinal cord. Eur J Neurosci 2004; 20: 1769-78.
79. Slack SE, Thompson SW,. Brain-derived neurotrophic factor induces NMDA receptor 1 phosphorylation in rat spinal cord. Neuroreport 2002; 13: 1967-70.
80. Hu HJ, Carrasquillo Y, Karim F, et al. The kv4.2 potassium channel subunit is required for pain plasticity. Neuron 2006; 50: 89-100.
81. Hu HJ, Gereau RW,. Metabotropic glutamate receptor 5 regulates excitability and Kv4.2-containing K(+) channels primarily in excitatory neurons of the spinal dorsal horn. J Neurophysiol 2011; 105: 3010-21.
82. Andersson KE, Schröder A,. Pharmacology of the lower urinary tract. In:, Corcos J, Schick E, editors. Textbook of the neurogenic bladder. London: Martin Dunitz Ltd; 2004. pp. 57-72.
83. de Groat WC, Yoshimura N,. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 2001; 41: 691-721.
84. Charrua A, Cruz CD, Cruz F, et al. Transient receptor potential vanilloid subfamily 1 is essential for the generation of noxious bladder input and bladder overactivity in cystitis. J Urol 2007; 177: 1537-41.
85. Mukerji G, Yiangou Y, Agarwal SK, et al. Transient receptor potential vanilloid receptor subtype 1 in painful bladder syndrome and its correlation with pain. J Urol 2006; 176: 797-801.
86. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-82, discussion 973-82.
87. Szallasi A, Cruz F, Geppetti P,. TRPV1: A therapeutic target for novel analgesic drugs ? Trends Mol Med 2006; 12: 545-54.
88. Moran MM, McAlexander MA, Biro T, et al. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov 2011; 10: 601-20.
89. Yoshimura N, Kaiho Y, Miyazato M, et al. Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 437-48.
90. Chuang HH, Prescott ED, Kong H, et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001; 411: 957-62.
91. Shinoda M, Asano M, Omagari D, et al. Nerve growth factor contribution via transient receptor potential vanilloid 1 to ectopic orofacial pain. J Neurosci 2011; 31: 7145-55.
92. Bron R, Klesse LJ, Shah K, et al. Activation of Ras is necessary and sufficient for upregulation of vanilloid receptor type 1 in sensory neurons by neurotrophic factors. Mol Cell Neurosci 2003; 22: 118-32.
93. Bonnington JK, McNaughton PA,. Signalling pathways involved in the sensitisation of mouse nociceptive neurones by nerve growth factor. J Physiol 2003; 551: 433-46.
94. Zhang X, Huang J, McNaughton PA,. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 2005; 24: 4211-23.
95. Frias B, Charrua A, Avelino A, et al. Transient receptor potential vanilloid 1 mediates nerve growth factor-induced bladder hyperactivity and noxious input. BJU Int 2012; 110: E422-8.
96. Okragly AJ, Niles AL, Saban R, et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol 1999; 161: 438-41, discussion 432-41.
97. Kim JC, Park EY, Hong SH, et al. Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int J Urol 2005; 12: 875-80.
98. Kim JC, Park EY, Seo SI, et al. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006; 175: 1773-6, discussion 1776.
99. Jacobs BL, Smaldone MC, Tyagi V, et al. Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can J Urol 2010; 17: 4989-94.
100. Liu HT, Chancellor MB, Kuo HC,. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 2009; 103: 1668-72.
101. Liu HT, Chen CY, Kuo HC,. Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int 2011; 107: 799-803.
102. Liu HT, Kuo HC,. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 2008; 72: 104-8, discussion 108.
103. Liu HT, Kuo HC,. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol Urodyn 2009; 28: 78-81.
104. Liu HT, Liu AB, Chancellor MB, et al. Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident. BJU Int 2009; 104: 1158-62.
105. Oktar T, Kocak T, Oner-Iyidogan Y, et al. Urinary nerve growth factor in children with overactive bladder: A promising, noninvasive and objective biomarker. J Ped Urol 2012. DOI: 10.1016/j.jpurol.2012.06.003
106. Yokoyama T, Kumon H, Nagai A,. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodyn 2008; 27: 417-20.
107. Antunes-Lopes T, Pinto R, Barros SC, et al. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol 2013; 189: 359-65.
108. Pinto R, Lopes T, Frias B, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2010; 58: 360-5.
109. Antunes-Lopes T, Carvalho-Barros S, Cruz CD, et al. Biomarkers in overactive bladder: A new objective and noninvasive tool ? Adv Urol 2011; 2011: 382431.
110. Kuo HC, Liu HT, Chancellor MB,. Can urinary nerve growth factor be a biomarker for overactive bladder ? Rev Urol 2010; 12: e69-77.
111. Kuo HC, Liu HT, Chancellor MB,. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn 2010; 29: 482-7.
112. Liu HT, Kuo HC,. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 2008; 179: 2270-4.
113. Liu HT, Chancellor MB, Kuo HC,. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int 2008; 102: 1440-4.
114. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010; 363: 1521-31.
115. Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces osteoarthritic knee pain: Results of a randomized, double-blind, placebo-controlled phase III trial. J Pain 2012; 13: 790-8.
116. Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces osteoarthritic hip pain: Results of a randomized, double-blind, placebo-controlled phase 3 trial. Arthritis Rheum 2013; doi: 10.1002/art.37950. Epub ahead of print.
117. Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol 2011; 185: 1716-21.
118. Nickel JC, Atkinson G, Krieger JN, et al. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome. Urology 2012; 80: 1105-10.
119. Holmes D,. Anti-NGF painkillers back on track ? Nat Rev Drug Discov 2012; 11: 337-8.
120. Barouch R, Appel E, Kazimirsky G, et al. Macrophages express neurotrophins and neurotrophin receptors. Regulation of nitric oxide production by NT-3. J Neuroimmunol 2001; 112: 72-7.
121. Kawamoto K, Okada T, Kannan Y, et al. Nerve growth factor prevents apoptosis of rat peritoneal mast cells through the Trk proto-oncogene receptor. Blood 1995; 86: 4638-44.
122. Tabakman R, Lecht S, Sephanova S, et al. Interactions between the cells of the immune and nervous system: Neurotrophins as neuroprotection mediators in CNS injury. Prog Brain Res 2004; 146: 387-401.
123. Hanno P, Andersson KE, Birder L, et al. Chronic pelvic pain syndrome/bladder pain syndrome: Taking stock, looking ahead: ICI-RS 2011. Neurourol Urodyn 2012; 31: 375-83.
124. Hanno PM, Burks DA, Clemens JQ, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 2011; 185: 2162-70.
125. Haas L, Portela LV, Bohmer AE, et al. Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia. Neurochem Res 2010; 35: 830-4.
126. Gold SM, Schulz KH, Hartmann S, et al. Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls. J Neuroimmunol 2003; 138: 99-105.
127. Hashimoto K,. Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions. Psychiatry Clin Neurosci 2010; 64: 341-57.
128. Liu HT, Lin H, Kuo HC,. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Neurourol Urodyn 2011; 30: 1525-9.